SEC Company Response from Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747) (SCNI) — May 11, 2015
Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)
Date: May 11, 2015 · CIK: 0001611747 · Accession: 0001213900-15-003459
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-201283
Letter
AEGIS CAPITAL CORP.
810 Seventh Avenue
18th Floor
New York, NY 10019
May 11, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Biondvax Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed May 6, 2015
File No. 333-201283
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the underwriters (the “Representative”), hereby join in the request of Biondvax Pharmaceuticals Ltd. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on Monday, May 11, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative of the underwriters, represent that the underwriters have and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
810 Seventh Avenue
18th Floor
New York, NY 10019
May 11, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Biondvax Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed May 6, 2015
File No. 333-201283
Ladies and Gentlemen:
In accordance with
the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative
of the underwriters (the “Representative”), hereby join in the request of Biondvax Pharmaceuticals Ltd. that the effective
date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern
Time, on Monday, May 11, 2015, or as soon thereafter as practicable.
Pursuant to Rule
460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably
anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary
prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned,
as the representative of the underwriters, represent that the underwriters have and will comply with the requirements of Rule 15c2-8
under the Securities Exchange Act of 1934, as amended.
Very truly yours,
AEGIS CAPITAL CORP.
As Representative of the several underwriters named in
Schedule I to the Underwriting Agreement
By:
AEGIS CAPITAL CORP.
By:
/s/ Anthony Monaco
Name: Anthony M. Monaco
Title: Chief Compliance Officer